Atlas Trials

Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders

Clinical trial NCT03601819 · TERMINATED

Trial details

NCT number
NCT03601819
Sponsor
University of Michigan Rogel Cancer Center
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Lymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralChronic Lymphocytic LeukemiaLymphoproliferative DisordersWaldenstrom MacroglobulinemiaLymphoplasmacytic LymphomaMantle Cell Lymphoma
Start date
2019-05-15
Primary completion
2020-03-07
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.